McKesson and Clayton, Dubilier & Rice have struck a $5.8 billion agreement to acquire Option Care Health, the largest independent provider of home and alternate-site infusion services in the United States, in a deal that highlights the continuing consolidation of healthcare services assets with defensive earnings profiles.
The transaction, announced after market hours, values Option Care at $32.05 per share and would take the company private if completed. For McKesson, one of the largest healthcare distribution and services groups in the world, the move deepens its exposure to specialty care and patient services. For CD&R, the buyout firm with a long record in healthcare and industrial investments, the deal fits a familiar pattern: backing businesses that benefit from scale, reimbursement complexity and long-term demand trends.
Care Delivery Shift
Option Care sits at the intersection of two powerful structural trends in U.S. healthcare: the migration of treatment away from inpatient settings and the growing use of infusion therapies for chronic and acute conditions. The company provides medications and clinical support to patients receiving treatment at home or in alternate sites, a model that can lower costs for payers while offering convenience for patients and capacity relief for hospitals.
That positioning has made the business attractive to strategic buyers and financial sponsors alike. At-home infusion services are not a high-growth consumer story, but they are a durable one. Demand is tied to the prevalence of chronic disease, the expansion of specialty pharmaceuticals and the broader push by insurers and providers to shift appropriate care out of expensive hospital environments.
The acquisition also reflects a broader M&A theme in healthcare: buyers are paying for predictable revenue streams and operational scale rather than pure growth. In a market where capital remains selective and public investors have often punished healthcare names with reimbursement exposure, assets such as Option Care can command premium attention when they combine recurring demand with national reach.
Strategic Fit For Buyers
McKesson's involvement is especially notable. The company has spent years reshaping itself beyond traditional drug distribution, building a larger presence in oncology, specialty pharmacy and patient support services. Option Care would extend that strategy by adding a platform closely linked to specialty drug administration and care coordination.
CD&R, meanwhile, has often partnered with strategic operators or management teams to unlock value in businesses with strong market positions but complex operating models. In this case, the private equity firm appears to be betting that Option Care can be run with greater flexibility away from public markets, while benefiting from the operational and commercial reach of a large healthcare partner.
The deal structure suggests confidence that the business can continue generating steady cash flow even in a more demanding reimbursement environment. It also signals that large buyers still see value in healthcare services companies despite a tougher financing backdrop than the one that prevailed during the low-rate era.
Market Implications
For public investors, the transaction is another reminder that healthcare equities with stable earnings and niche leadership can become acquisition targets when strategic buyers are willing to pay for scale. It may also reinforce expectations that more specialty care and services companies could be drawn into take-private transactions if their valuations remain below the levels buyers believe reflect their long-term worth.
The acquisition comes at a time when healthcare markets are under pressure from policy scrutiny, cost containment efforts and ongoing debate over the economics of care delivery. Yet those same pressures can make businesses like Option Care more appealing, because they are often positioned as lower-cost alternatives to hospital-based treatment.
The deal will now move through customary regulatory and shareholder approvals. If completed, it would mark one of the larger healthcare services transactions of the year and further consolidate a sector where scale, contracting power and operational execution increasingly determine competitive advantage.
For McKesson, the transaction offers another step in its evolution from a traditional distributor into a broader healthcare platform. For CD&R, it is a wager that a business built around essential therapies and decentralized care can deliver resilient returns in both public and private ownership.